Table 4. Multiple regression analysis that correlates the effect of the variant KIF6 on the Non-HDL cholesterol concentration adjusted by statistically significant covariates.

Changes in Serum Non-HDL Cholesterol concentration after treatment; (%)
Treatment	Model	Variables	B + CI (95%)	P
Simvastatin+Atorvastatin+Rosuvastatin	Additive	Genotypes: TT, TC, and CC	0.8 (-1.7 to 3.4)	0.535
		Intensity of qualitative treatment	-4.4 (-7.2 to -1.5)	0.003*
		Initial concentration of c-Non-HDL	-2.6 (-4.0 to -1.2)	2.6x10-4*
Simvastatin+ Atorvastatin	Additive	Genotypes: TT, TC, and CC	1.7 (-0.9 to 4.4)	0.200
		Intensity of qualitative treatment	-5.3 (-8.2 to 2.3)	4.0x10-4*
		Initial concentration of c-LDL	-2.6 (-4.0 to -1.2)	2.2x10-4*
	Recessive	KIF6 (CC compared to T)	5.1 (0.1 to 10.1)	0.045*
		Intensity of qualitative treatment	-5.4 (-8.2 to -2.5)	2.8x10-4*
		Initial concentration of c-LDL	-2.6 (-4.0 to -1.2)	2.6x10-4*
Simvastatin	Additive	Genotypes: TT, TC, and CC	1.2 (-2.2 to 4.7)	0.504
		Initial concentration of c-Non-HDL	-3.4 (-5.4 to -1.3)	0.001*
Atorvastatin	Additive	Genotypes: TT, TC, and CC	3.6 (-0.4 to 7.6)	0.070
		Intensity of qualitative treatment	-6.2 (-10.6 to -1.8)	0.006*
		Initial concentration of c-Non-HDL	-2.8 (-4.7 to -1)	0.004*
		Age	-0.3 (-0.5 to 0.1)	0.001*
	Recessive	KIF6 (CC compared to T)	9.03 (2.1 to 16.5)	0.012*
		Intensity of qualitative treatment	-6.8 (-11.1 to -2.4)	0.003*
		Initial concentration of c-Non-HDL	-2.8 (-4.7 to -1.0)	0.003*
		Age	0.35 (0.15 to 0.54)	0.001*
Rosuvastatin	Additive	Genotypes: TT, TC, and CC	-3.4 (-12.9 to 6.0)	0.463
		Prior MACE	-15.4 (-33-3 to 2.5)	0.089

B+CI (95%) = coefficient B + a 95% confidence interval

* indicates statistical significance.